437 related articles for article (PubMed ID: 24603946)
21. [Passive Tau immunotherapy for prevention of Tau pathology progression].
Ozmen L; Collin L
Med Sci (Paris); 2015 Feb; 31(2):132-4. PubMed ID: 25744257
[No Abstract] [Full Text] [Related]
22. Near Infrared Light Treatment Reduces Synaptic Levels of Toxic Tau Oligomers in Two Transgenic Mouse Models of Human Tauopathies.
Comerota MM; Tumurbaatar B; Krishnan B; Kayed R; Taglialatela G
Mol Neurobiol; 2019 May; 56(5):3341-3355. PubMed ID: 30120733
[TBL] [Abstract][Full Text] [Related]
23. Advances in therapeutics for neurodegenerative tauopathies: moving toward the specific targeting of the most toxic tau species.
Gerson JE; Castillo-Carranza DL; Kayed R
ACS Chem Neurosci; 2014 Sep; 5(9):752-69. PubMed ID: 25075869
[TBL] [Abstract][Full Text] [Related]
24. Neurofibrillary tangle formation by introducing wild-type human tau into APP transgenic mice.
Umeda T; Maekawa S; Kimura T; Takashima A; Tomiyama T; Mori H
Acta Neuropathol; 2014 May; 127(5):685-98. PubMed ID: 24531886
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of immunization with phosphorylated tau against neurofibrillary tangles in mice.
Boimel M; Grigoriadis N; Lourbopoulos A; Haber E; Abramsky O; Rosenmann H
Exp Neurol; 2010 Aug; 224(2):472-85. PubMed ID: 20546729
[TBL] [Abstract][Full Text] [Related]
26. Passive immunization with phospho-tau antibodies reduces tau pathology and functional deficits in two distinct mouse tauopathy models.
Sankaranarayanan S; Barten DM; Vana L; Devidze N; Yang L; Cadelina G; Hoque N; DeCarr L; Keenan S; Lin A; Cao Y; Snyder B; Zhang B; Nitla M; Hirschfeld G; Barrezueta N; Polson C; Wes P; Rangan VS; Cacace A; Albright CF; Meredith J; Trojanowski JQ; Lee VM; Brunden KR; Ahlijanian M
PLoS One; 2015; 10(5):e0125614. PubMed ID: 25933020
[TBL] [Abstract][Full Text] [Related]
27. Combined effects of scanning ultrasound and a tau-specific single chain antibody in a tau transgenic mouse model.
Nisbet RM; Van der Jeugd A; Leinenga G; Evans HT; Janowicz PW; Götz J
Brain; 2017 May; 140(5):1220-1230. PubMed ID: 28379300
[TBL] [Abstract][Full Text] [Related]
28. Intercellular transfer of tau aggregates and spreading of tau pathology: Implications for therapeutic strategies.
Clavaguera F; Grueninger F; Tolnay M
Neuropharmacology; 2014 Jan; 76 Pt A():9-15. PubMed ID: 24050961
[TBL] [Abstract][Full Text] [Related]
29. The role of tau oligomers in the onset of Alzheimer's disease neuropathology.
Cárdenas-Aguayo Mdel C; Gómez-Virgilio L; DeRosa S; Meraz-Ríos MA
ACS Chem Neurosci; 2014 Dec; 5(12):1178-91. PubMed ID: 25268947
[TBL] [Abstract][Full Text] [Related]
30. Tau oligomers as potential targets for early diagnosis of tauopathy.
Sahara N; Ren Y; Ward S; Binder LI; Suhara T; Higuchi M
J Alzheimers Dis; 2014; 40 Suppl 1():S91-6. PubMed ID: 24595194
[TBL] [Abstract][Full Text] [Related]
31. TOC1: a valuable tool in assessing disease progression in the rTg4510 mouse model of tauopathy.
Ward SM; Himmelstein DS; Ren Y; Fu Y; Yu XW; Roberts K; Binder LI; Sahara N
Neurobiol Dis; 2014 Jul; 67():37-48. PubMed ID: 24631720
[TBL] [Abstract][Full Text] [Related]
32. Tau oligomers as potential targets for immunotherapy for Alzheimer's disease and tauopathies.
Lasagna-Reeves CA; Castillo-Carranza DL; Jackson GR; Kayed R
Curr Alzheimer Res; 2011 Sep; 8(6):659-65. PubMed ID: 21605039
[TBL] [Abstract][Full Text] [Related]
33. Tauopathy contributes to synaptic and cognitive deficits in a murine model for Alzheimer's disease.
Stancu IC; Ris L; Vasconcelos B; Marinangeli C; Goeminne L; Laporte V; Haylani LE; Couturier J; Schakman O; Gailly P; Pierrot N; Kienlen-Campard P; Octave JN; Dewachter I
FASEB J; 2014 Jun; 28(6):2620-31. PubMed ID: 24604080
[TBL] [Abstract][Full Text] [Related]
34. 'Prion-like' propagation of mouse and human tau aggregates in an inducible mouse model of tauopathy.
Sydow A; Mandelkow EM
Neurodegener Dis; 2010; 7(1-3):28-31. PubMed ID: 20160454
[TBL] [Abstract][Full Text] [Related]
35. Absence of microglia or presence of peripherally-derived macrophages does not affect tau pathology in young or old hTau mice.
Zhu K; Pieber M; Han J; Blomgren K; Zhang XM; Harris RA; Lund H
Glia; 2020 Jul; 68(7):1466-1478. PubMed ID: 32039516
[TBL] [Abstract][Full Text] [Related]
36. Resveratrol Rescues Tau-Induced Cognitive Deficits and Neuropathology in a Mouse Model of Tauopathy.
Sun XY; Dong QX; Zhu J; Sun X; Zhang LF; Qiu M; Yu XL; Liu RT
Curr Alzheimer Res; 2019; 16(8):710-722. PubMed ID: 31368873
[TBL] [Abstract][Full Text] [Related]
37. Novel Phospho-Tau Monoclonal Antibody Generated Using a Liposomal Vaccine, with Enhanced Recognition of a Conformational Tauopathy Epitope.
Theunis C; Adolfsson O; Crespo-Biel N; Piorkowska K; Pihlgren M; Hickman DT; Gafner V; Borghgraef P; Devijver H; Pfeifer A; Van Leuven F; Muhs A
J Alzheimers Dis; 2017; 56(2):585-599. PubMed ID: 28035925
[TBL] [Abstract][Full Text] [Related]
38. Azure C Targets and Modulates Toxic Tau Oligomers.
Lo Cascio F; Kayed R
ACS Chem Neurosci; 2018 Jun; 9(6):1317-1326. PubMed ID: 29378132
[TBL] [Abstract][Full Text] [Related]
39. α-Synuclein Oligomers Induce a Unique Toxic Tau Strain.
Castillo-Carranza DL; Guerrero-Muñoz MJ; Sengupta U; Gerson JE; Kayed R
Biol Psychiatry; 2018 Oct; 84(7):499-508. PubMed ID: 29478699
[TBL] [Abstract][Full Text] [Related]
40. Caspase-cleaved tau exhibits rapid memory impairment associated with tau oligomers in a transgenic mouse model.
Kim Y; Choi H; Lee W; Park H; Kam TI; Hong SH; Nah J; Jung S; Shin B; Lee H; Choi TY; Choo H; Kim KK; Choi SY; Kayed R; Jung YK
Neurobiol Dis; 2016 Mar; 87():19-28. PubMed ID: 26704708
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
